axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Company profile
Ticker
AXSM
Exchange
Website
CEO
Herriot Tabuteau
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Axsome Therapeutics Australia Pty Ltd • Axsome Therapeutics, Limited • Axsome International Holdings LLC • Axsome Malta Holdings Ltd. • Axsome Malta Ltd. • Axsome Canada, Inc. ...
AXSM stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
6 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
1 Apr 24
8-K
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
25 Mar 24
8-K
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25 Mar 24
8-K
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
19 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Corporate Presentation February 2024
20 Feb 24
Transcripts
AXSM
Earnings call transcript
2024 Q1
6 May 24
AXSM
Earnings call transcript
2023 Q4
20 Feb 24
AXSM
Earnings call transcript
2023 Q3
6 Nov 23
AXSM
Earnings call transcript
2023 Q2
7 Aug 23
AXSM
Earnings call transcript
2023 Q2
7 Aug 23
AXSM
Earnings call transcript
2023 Q1
8 May 23
AXSM
Earnings call transcript
2022 Q4
27 Feb 23
AXSM
Earnings call transcript
2022 Q3
7 Nov 22
AXSM
Earnings call transcript
2022 Q2
9 Aug 22
AXSM
Earnings call transcript
2022 Q1
2 May 22
Latest ownership filings
4
Mark L. Jacobson
29 May 24
4
Mark Coleman
29 May 24
144
Notice of proposed sale of securities
29 May 24
144
Notice of proposed sale of securities
29 May 24
144
Notice of proposed sale of securities
28 May 24
4
Mark L. Jacobson
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
ROGER JEFFS
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 331.44 mm | 331.44 mm | 331.44 mm | 331.44 mm | 331.44 mm | 331.44 mm |
Cash burn (monthly) | 18.25 mm | (no burn) | 22.79 mm | 24.83 mm | 17.82 mm | 16.06 mm |
Cash used (since last report) | 38.28 mm | n/a | 47.79 mm | 52.09 mm | 37.38 mm | 33.69 mm |
Cash remaining | 293.16 mm | n/a | 283.65 mm | 279.35 mm | 294.06 mm | 297.75 mm |
Runway (months of cash) | 16.1 | n/a | 12.4 | 11.2 | 16.5 | 18.5 |
Institutional ownership, Q1 2024
4.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 84 |
Opened positions | 21 |
Closed positions | 113 |
Increased positions | 20 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 156.84 bn |
Total shares | 2.14 mm |
Total puts | 214.50 k |
Total calls | 158.80 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
First Turn Management | 342.17 k | $27.31 bn |
BK Bank Of New York Mellon | 153.77 k | $12.27 bn |
USB U.S. Bancorp. | 133.51 k | $10.65 bn |
Iridian Asset Management | 128.84 k | $10.28 bn |
WCM Investment Management | 111.59 k | $8.90 bn |
Peregrine Capital Management | 86.14 k | $6.87 bn |
Lindbrook Capital | 83.77 k | $6.68 bn |
BNP Paribas Arbitrage | 82.54 k | $6.59 bn |
Fund Management B.V. Privium | 82.03 k | $6.55 bn |
Candriam Luxembourg S.C.A. | 75.08 k | $5.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 May 24 | Mark L. Jacobson | Common Stock | Sell | Dispose S | No | No | 74.3127 | 7,910 | 587.81 k | 5,783 |
29 May 24 | Mark L. Jacobson | Common Stock | Option exercise | Acquire M | No | No | 1.3 | 13,693 | 17.80 k | 13,693 |
29 May 24 | Mark L. Jacobson | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.3 | 13,693 | 17.80 k | 0 |
29 May 24 | Coleman Mark | Common Stock | Sell | Dispose S | No | No | 75.1396 | 5,248 | 394.33 k | 14,600 |
28 May 24 | Coleman Mark | Common Stock | Sell | Dispose S | No | No | 75.2095 | 5,249 | 394.77 k | 19,848 |
1 Apr 24 | Mark L. Jacobson | Common Stock | Sell | Dispose S | No | No | 77.242 | 24,662 | 1.90 mm | 0 |
1 Apr 24 | Mark L. Jacobson | Common Stock | Option exercise | Acquire M | No | No | 1.3 | 24,662 | 32.06 k | 24,662 |
1 Apr 24 | Mark L. Jacobson | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.3 | 24,662 | 32.06 k | 0 |
15 Mar 24 | Jeffs Roger | Common Stock | Sell | Dispose S | No | No | 71.6072 | 2,347 | 168.06 k | 120,756 |
15 Mar 24 | Jeffs Roger | Common Stock | Option exercise | Acquire M | No | No | 29.91 | 2,347 | 70.20 k | 123,103 |
News
Axsome Unveils New Findings on Auvelity and AXS-05 for Central Nervous System (CNS) Disorders at ASCP Conference
28 May 24
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
28 May 24
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
8 May 24
Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125
7 May 24
Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $112
7 May 24
Press releases
Axsome Therapeutics to Participate in Upcoming Investor Conferences
30 May 24
Axsome Therapeutics to Present at Upcoming Investor Conferences
8 May 24
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
6 May 24
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
1 May 24
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
30 Apr 24